ShOckwave ballooN or Atherectomy With Rotablation in Calcified Coronary Artery Lesions, the SONAR Trial

Coronary Artery Disease Clinical Trial

— SONAR  

Official title:

A Randomized Controlled Trial Comparing Rates of Peri-procedural Myocardial Infarction After Intravascular Ultrasound and Rotational Atherectomy in Patients With Calcified Coronary Artery Lesions

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05208749
• Other study ID #: S64676
• Status: Recruiting
• Phase: N/A
• Start date: February 4, 2022
• Est. completion date: January 1, 2025

Study information

• Verified date: January 2022
• Source: Universitaire Ziekenhuizen Leuven
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Percutaneous coronary interventions (PCI) is intended to relieve myocardial ischemia by improving blood flow in the epicardial coronary arteries. However, the efficacy of PCI may be compromised by incidental microvascular obstruction and peri-procedural myocardial infarction (PPMI), which occurs in about 10-15% of cases and is associated with increased rates of major adverse cardiovascular events (MACE). The mechanism of PPMI is thought to be related to side branch occlusion, coronary artery dissection and acute microvascular damage caused by embolization of plaque debris during the PCI and is more frequently seen in calcified coronary artery disease. Calcium modification by rotational atherectomy (RA) results in peri-procedural myocardial infarction in 24% of cases and myocardial injury in 70% of cases. The Shockwave coronary intravascular lithotripsy (IVL) balloon catheter emits sonic pressure waves in a circumferential field causing the selective fracture of calcium, altering vessel compliance and permitting further expansion of the vessel wall. This provides a potentially safer alternative to other calcium-modifying devices since there is a low risk of dissection and perforation. It is also proposed that this IVL device reduces the risk of atheromatous embolization, which would reduce the risk of PPMI and microvascular dysfunction. The SONAR Trial is a pilot study measuring peri-procedural myocardial injury, PPMI and microvascular dysfunction in patients (with calcified coronary artery lesions not responding to usual balloon dilatation) randomized to RA or Shockwave IVL. The primary outcome is peri-procedural myocardial infarction. Secondary outcomes include peri-procedural myocardial injury, acute microvascular dysfunction, procedural success, and procedural costs.

Description:

In this multicentre, prospective, randomized-controlled open label pilot study the investigators will measure rates of peri-procedural myocardial infarction and changes in microvascular function after PCI in 170 patients (85 per arm) treated with Shockwave intravascular lithotripsy (IVL) versus RA. Patients with moderately and/or severely calcified coronary lesions, which are equally suitable for IVL and RA and do not dilate fully (100%) with an appropriately sized non-compliant balloon at 16 atmospheres, will be recruited. The calcified lesion must be suitable for both IVL and RA and the operator believes that either IVL or RA could be used. The primary outcome will be difference in the rate of peri-procedural myocardial infarction (Type 4a of the universal Definition of Myocardial Infarction). Peri-procedural myocardial injury and infarction will be defined by an increase in high-sensitivity Troponin T according to the Fourth Universal Definition of Myocardial Infarction,15 while microvascular dysfunction will be defined by an Index of Microcirculatory Resistance (IMR) of ≥25.16 Patients will undergo study-related clinical follow up at 30 days and 12 months.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 170
• Est. completion date: January 1, 2025
• Est. primary completion date: January 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient older than 18 years.
• The subject has stable or unstable angina pectoris, or a positive functional study for ischemia.
• The subject is eligible for PCI.
• The subject gives consent prior to study inclusion.
• The subject has a calcified lesion that does not dilated fully after balloon angioplasty at 16atm with a =2.5mm non-compliant balloon.
• The calcified lesion has a 50-90% diameter stenosis by angiographic assessment.

Exclusion Criteria:

• Previous and/or planned brachytherapy of target vessel.
• Pregnant and/or breast-feeding females or females who intend to become pregnant.
• Patients who intend to have a major surgical intervention within 6 months of enrolment in the study.
• Patients who previously participated in this study.
• Subject has experienced an acute myocardial infarction 72 hours prior to the index procedure, as defined either by the presence of a new Q-wave in 2 or more contiguous leads, or by a CK greater than two times site upper reference limit (URL) with presence of CK-MB greater than the site URL.
• The subject has suffered a stroke or transient ischemic neurological attack or cerebrovascular accident within the past six months, or has any known intracranial mass, arteriovenous malformation, aneurysm or other intracranial pathology.
• The subject has experienced a significant gastrointestinal or genitourinary bleed within the past six months, or has had any active bleeding within two months.
• Planned revascularization of target vessel within 1 year after index procedure.
• Lesions not ideal for Shockwave treatment:
• Longer than 40mm.
• The target vessel contains intraluminal thrombus.
• The subject has had a prior stent in the target lesion, including a 5mm zone proximal and distal to the lesion.

Related Conditions & MeSH terms

• Calcified Atheroma
• Coronary Artery Disease
• Plaque, Atherosclerotic

Intervention

Device:
• Rotablation of shockwave
Patients will be randomized to treatment with rotablation or shockwave

Locations

Country	Name	City	State
Belgium	University Hopsitals Leuven	Leuven	Brabant

Sponsors (9)

Lead Sponsor	Collaborator
Universitaire Ziekenhuizen Leuven	AZ St- Jan Brugge, Centre Hospitalier Universitaire Saint Pierre, Hôpital Jolimont, Imelda Hospital, Bonheiden, Universitair Ziekenhuis Brussel, University Hospital, Ghent, Ziekenhuis Netwerk Antwerpen (ZNA), Ziekenhuis Oost-Limburg

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference in peri-procedural myocardial infarction (Type 4a)	Measurements of HS Troponine T at 8hrs, 16hrs and 24 hrs post PCI	within 24 hours of index PCI
Secondary	Procedural differences (technical and procedural success, procedural characteristics and costs).	procedural characteristics	periprocedural
Secondary	Difference in change in IMR between the two groups.	measurement of IMR before and after PCI	periprocedural
Secondary	Clinical outcomes at 30-days and 1 year.	clinical outcomes (Major adverse clinical events, including MI, TLR and cardiac death)	1 year
Secondary	IMR change post-PCI in calcified lesions	measurement of IMR before and after PCI	periprocedural
Secondary	Peri-procedural myocardial injury incidence	Measurements of HS Troponine T at 8hrs, 16hrs and 24 hrs post PCI	periprocedural